175 related articles for article (PubMed ID: 36960680)
41. DNMT3A (R882) mutation features and prognostic effect in acute myeloid leukemia in Coexistent with NPM1 and FLT3 mutations.
Kumar D; Mehta A; Panigrahi MK; Nath S; Saikia KK
Hematol Oncol Stem Cell Ther; 2018 Jun; 11(2):82-89. PubMed ID: 29079128
[TBL] [Abstract][Full Text] [Related]
42. Mutational spectrum of
Pettersson L; Holmgren B; Juliusson G; Lazarevic VL; Ehinger M
Leuk Lymphoma; 2021 Aug; 62(8):1958-1966. PubMed ID: 33711909
[TBL] [Abstract][Full Text] [Related]
43. [Using next generation sequencing technology to analyze gene mutations in patients with acute myeloid leukemia and the impact on prognosis].
Zhao CX; Wang JM; Li JM; Zou SH; Chen FY; Liang AB; Hou J; Hu XX; Zhang YX; Gu SY; Zhu JY; Li P; Du J; Yang YN; Qin YW; Wang XR; Wang C
Zhonghua Yi Xue Za Zhi; 2019 Oct; 99(40):3145-3151. PubMed ID: 31694105
[No Abstract] [Full Text] [Related]
44. Myeloid Sarcoma Involving the Testis in Adults: Clonal Evolution of Acute Myeloid Leukemia.
Nichols MM; Cook JR; Bosler DS; Rogers HJ; Philip JKSS; Jogenpally NR; Reynolds JP; Robertson S; Cotta CV
Appl Immunohistochem Mol Morphol; 2022 Apr; 30(4):e32-e39. PubMed ID: 35001036
[TBL] [Abstract][Full Text] [Related]
45. [Clinical characteristics of newly diagnosed acute myeloid leukemia patients with NPM1 mutation].
Wei H; Zhang YQ; Lin D; Wang Y; Zhou CL; Liu BC; Li W; Rao Q; Wang M; Mi YC; Wang JX
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Feb; 22(1):11-5. PubMed ID: 24598642
[TBL] [Abstract][Full Text] [Related]
46. Clinical Effect of Combined Mutations in DNMT3A, FLT3-ITD, and NPM1 Among Egyptian Acute Myeloid Leukemia Patients.
El Gammal MM; Ebid GT; Madney YM; Abo-Elazm OM; Kelany AK; Torra OS; Radich JP
Clin Lymphoma Myeloma Leuk; 2019 Jun; 19(6):e281-e290. PubMed ID: 30926392
[TBL] [Abstract][Full Text] [Related]
47. Biological and clinical influences of
Yang X; Shi J; Zhang X; Zhang G; Zhang J; Yang S; Wang J; Ke X; Fu L
Cancer Manag Res; 2018; 10():2489-2497. PubMed ID: 30122998
[TBL] [Abstract][Full Text] [Related]
48. NPM1-mutated acute myeloid leukemia: from bench to bedside.
Falini B; Brunetti L; Sportoletti P; Martelli MP
Blood; 2020 Oct; 136(15):1707-1721. PubMed ID: 32609823
[TBL] [Abstract][Full Text] [Related]
49. Impact of the variant allele frequency of ASXL1, DNMT3A, JAK2, TET2, TP53, and NPM1 on the outcomes of patients with newly diagnosed acute myeloid leukemia.
Sasaki K; Kanagal-Shamanna R; Montalban-Bravo G; Assi R; Jabbour E; Ravandi F; Kadia T; Pierce S; Takahashi K; Nogueras Gonzalez G; Patel K; Soltysiak KA; Cortes J; Kantarjian HM; Garcia-Manero G
Cancer; 2020 Feb; 126(4):765-774. PubMed ID: 31742675
[TBL] [Abstract][Full Text] [Related]
50. FLT3 and NPM1 mutations in a cohort of AML patients and detection of a novel mutation in tyrosine kinase domain of FLT3 gene from Western India.
Ghosh K; Swaminathan S; Madkaikar M; Gupta M; Kerketta L; Vundinti B
Ann Hematol; 2012 Nov; 91(11):1703-12. PubMed ID: 22733614
[TBL] [Abstract][Full Text] [Related]
51. Acute myeloid leukemia with mutated NPM1 mimics acute promyelocytic leukemia presentation.
Arana Rosainz MJ; Nguyen N; Wahed A; Lelenwa LC; Aakash N; Schaefer K; Rios A; Kanaan Z; Chen L
Int J Lab Hematol; 2021 Apr; 43(2):218-226. PubMed ID: 33099879
[TBL] [Abstract][Full Text] [Related]
52. A distinct immunophenotype identifies a subset of NPM1-mutated AML with TET2 or IDH1/2 mutations and improved outcome.
Mason EF; Kuo FC; Hasserjian RP; Seegmiller AC; Pozdnyakova O
Am J Hematol; 2018 Aug; 93(4):504-510. PubMed ID: 29274134
[TBL] [Abstract][Full Text] [Related]
53. Favorable prognostic impact of NPM1 gene mutations in childhood acute myeloid leukemia, with emphasis on cytogenetically normal AML.
Hollink IH; Zwaan CM; Zimmermann M; Arentsen-Peters TC; Pieters R; Cloos J; Kaspers GJ; de Graaf SS; Harbott J; Creutzig U; Reinhardt D; van den Heuvel-Eibrink MM; Thiede C
Leukemia; 2009 Feb; 23(2):262-70. PubMed ID: 19020547
[TBL] [Abstract][Full Text] [Related]
54. The combination of NPM1, DNMT3A, and IDH1/2 mutations leads to inferior overall survival in AML.
Dunlap JB; Leonard J; Rosenberg M; Cook R; Press R; Fan G; Raess PW; Druker BJ; Traer E
Am J Hematol; 2019 Aug; 94(8):913-920. PubMed ID: 31145495
[TBL] [Abstract][Full Text] [Related]
55. Impact of FLT3 internal tandem duplication and NPM1 mutations in acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation.
Khanolkar RA; Faridi RM; Kinzel M; Jamani K; Savoie ML; Shafey M; Khan FM; Storek J
Cytotherapy; 2022 Apr; 24(4):413-420. PubMed ID: 34863627
[TBL] [Abstract][Full Text] [Related]
56. Acute myeloid leukemia with mutated nucleophosmin (NPM1): is it a distinct entity?
Falini B; Martelli MP; Bolli N; Sportoletti P; Liso A; Tiacci E; Haferlach T
Blood; 2011 Jan; 117(4):1109-20. PubMed ID: 21030560
[TBL] [Abstract][Full Text] [Related]
57. How I diagnose and treat NPM1-mutated AML.
Falini B; Brunetti L; Martelli MP
Blood; 2021 Feb; 137(5):589-599. PubMed ID: 33171486
[TBL] [Abstract][Full Text] [Related]
58. The characteristics and clinical prognosis analysis of ASXL1 mutations in Chinese adult patients with primary cytogenetically normal acute myeloid leukemia by next-generation sequencing.
Xu J; Hao Z; Chen X; Hong M; Muyey DM; Chen X; Wang H
Leuk Lymphoma; 2022 Oct; 63(10):2321-2329. PubMed ID: 35652795
[TBL] [Abstract][Full Text] [Related]
59. CD34 negative HLA-DR negative acute myeloid leukaemia: A higher association with NPM1 and FLT3-ITD mutations.
Gajendra S; Gupta R; Thakral D; Gupta SK; Jain G; Bakhshi S; Sharma A; Sahoo RK; Kumar L; Rai S; Singh S; Upadhyay AD
Int J Lab Hematol; 2023 Apr; 45(2):221-228. PubMed ID: 36504282
[TBL] [Abstract][Full Text] [Related]
60.
Kumar D; Mehta A; Panigrahi MK; Nath S; Saikia KK
Turk J Haematol; 2018 Mar; 35(1):49-53. PubMed ID: 29129825
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
